Overall, our results demonstrate that tumor-regenerating MM cells may be particularly susceptible to IL-16 neutralization, suggesting an important role of anti-IL-16 therapies in the treatment of MM, in particular in a sequential combination with existing strategies targeting the bulk of MM cells. This evidence concerns the gene IL16 and Miyoshi myopathy.